The minimal residual disease (MRD) testing market saw landmark trial readouts and commercial consolidation in 2025, led by the Phase III IMvigor011 study that used Natera’s tumor‑informed Signatera assay to select muscle‑invasive bladder cancer patients for adjuvant Tecentriq. Signatera‑positive patients who received Tecentriq showed statistically significant survival benefits, per ESMO presentations. Natera is finalizing a premarket application to the FDA for Signatera as a companion diagnostic, and multiple acquisitions and reimbursement wins signaled growing commercial validation. MRD testing detects circulating tumor DNA (ctDNA) to infer residual disease after curative‑intent therapy. Sources: conference presentations, Natera statements and industry analysts.